Ora Pharm completes Helius acquisition to establish export pathway

New Zealand medicinal cannabis firm Ora Pharm finishes Helius deal, signaling consolidation amid industry growth and regulatory scrutiny.

FILE — dealmaking · Perzon SEO / CC BY 2.0

Ora Pharm has completed its acquisition of Helius, according to MMJDaily. The deal positions the New Zealand firm to establish an export pathway—a significant step for a domestic medical cannabis industry that has faced operational challenges and market tightening over recent years.

The acquisition arrives as New Zealand's cannabis sector navigates competing pressures: a recent Massey University survey indicated cannabis is cheaper and more available than a decade ago, while industry growth has simultaneously slowed, with at least one major operator entering administration in March 2026. Ora Pharm's move toward export capability suggests confidence in scaling beyond the domestic market.

Key to watch: whether this transaction yields material export volumes and licensing approvals, and whether other New Zealand operators pursue similar consolidation or export strategies in response to domestic market constraints.